
Shulan Tian

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/10729730/publications.pdf Version: 2024-02-01



#	Article	lF	CITATIONS
1	Differential transcriptomic profiling in ibrutinibâ€naÃ⁻ve versus ibrutinibâ€resistant Richter syndrome. Hematological Oncology, 2022, 40, 302-306.	0.8	2
2	RBBP4-p300 axis modulates expression of genes essential for cell survival and is a potential target for therapy in glioblastoma. Neuro-Oncology, 2022, 24, 1261-1272.	0.6	6
3	Editorial: Clinical Genome Sequencing: Bioinformatics Challenges and Key Considerations. Frontiers in Genetics, 2022, 13, 896032.	1.1	0
4	Shared brain transcriptomic signature in TDP-43 type A FTLD patients with or without <i>GRN</i> mutations. Brain, 2022, 145, 2472-2485.	3.7	6
5	Epigenetic alteration contributes to the transcriptional reprogramming in T-cell prolymphocytic leukemia. Scientific Reports, 2021, 11, 8318.	1.6	3
6	Genetic variants related to successful migraine prophylaxis with verapamil. Molecular Genetics & Genomic Medicine, 2021, 9, e1680.	0.6	8
7	Heterogeneous delivery across the blood-brain barrier limits the efficacy of an EGFR-targeting antibody drug conjugate in glioblastoma. Neuro-Oncology, 2021, 23, 2042-2053.	0.6	37
8	Automated applicator digitization for high-dose-rate cervix brachytherapy using image thresholding and density-based clustering. Brachytherapy, 2020, 19, 111-118.	0.2	11
9	Chronic lymphocytic leukemia (CLL) risk is mediated by multiple enhancer variants within CLL risk loci. Human Molecular Genetics, 2020, 29, 2761-2774.	1.4	6
10	"Direct to Drug―screening as a precision medicine tool in multiple myeloma. Blood Cancer Journal, 2020, 10, 54.	2.8	20
11	Tumor mutational load predicts time to first treatment in chronic lymphocytic leukemia (CLL) and monoclonal Bâ€cell lymphocytosis beyond the CLL international prognostic index. American Journal of Hematology, 2020, 95, 906-917.	2.0	17
12	HLA class-I and class-II restricted neoantigen loads predict overall survival in breast cancer. Oncolmmunology, 2020, 9, 1744947.	2.1	26
13	Identification of a Novel Role for PD-1 Signaling in Promotion Tumor Proliferation in B-Cell Lymphoma. Blood, 2020, 136, 10-12.	0.6	0
14	Distinct Gene Expression Signatures in Patients with Richter's Syndrome and Chronic Lymphocytic Leukemia with Prior Exposure to Ibrutinib. Blood, 2020, 136, 30-31.	0.6	1
15	Genomic Profiling Reveals Molecular Heterogeneity in Patients with Richter's Syndrome (RS) and Progressive Chronic Lymphocytic Leukemia (CLL). Blood, 2020, 136, 16-17.	0.6	1
16	Extensive transcriptomic study emphasizes importance of vesicular transport in C9orf72 expansion carriers. Acta Neuropathologica Communications, 2019, 7, 150.	2.4	40
17	Recurrent MSCE116K mutations in ALK-negative anaplastic large cell lymphoma. Blood, 2019, 133, 2776-2789.	0.6	55
18	Pathogenic Germ Line Variants in a Patient With Severe Toxicity From Breast Radiotherapy. Clinical Breast Cancer, 2019, 19, e400-e405.	1.1	1

SHULAN TIAN

#	Article	IF	CITATIONS
19	Identification of factors associated with duplicate rate in ChIP-seq data. PLoS ONE, 2019, 14, e0214723.	1.1	6
20	Genome-wide analyses as part of the international FTLD-TDP whole-genome sequencing consortium reveals novel disease risk factors and increases support for immune dysfunction in FTLD. Acta Neuropathologica, 2019, 137, 879-899.	3.9	90
21	Comparative analysis of de novo assemblers for variation discovery in personal genomes. Briefings in Bioinformatics, 2018, 19, 893-904.	3.2	14
22	PD-1 Expression in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) and Large B-cell Richter Transformation (DLBCL-RT). American Journal of Surgical Pathology, 2018, 42, 843-854.	2.1	54
23	Identification of missing variants by combining multiple analytic pipelines. BMC Bioinformatics, 2018, 19, 139.	1.2	10
24	PARP Inhibitors for Sensitization of Alkylation Chemotherapy in Glioblastoma: Impact of Blood-Brain Barrier and Molecular Heterogeneity. Frontiers in Oncology, 2018, 8, 670.	1.3	60
25	Pembrolizumab in patients with CLL and Richter transformation or with relapsed CLL. Blood, 2017, 129, 3419-3427.	0.6	335
26	Comprehensive Platelet Phenotypic Laboratory Testing and Bleeding History Scoring for Diagnosis of Suspected Hereditary Platelet Disorders. American Journal of Clinical Pathology, 2017, 148, 23-32.	0.4	16
27	PRC2 specifies ectoderm lineages and maintains pluripotency in primed but not naÃ⁻ve ESCs. Nature Communications, 2017, 8, 672.	5.8	87
28	Analyses of Genome-Wide Histone Modifications in the Mammalian Genome. , 2017, , 135-152.		1
29	Genome-Wide Epigenetic Studies in Human Disease: A Primer on -Omic Technologies. American Journal of Epidemiology, 2016, 183, kwv187.	1.6	23
30	An analytical workflow for accurate variant discovery in highly divergent regions. BMC Genomics, 2016, 17, 703.	1.2	22
31	Impact of post-alignment processing in variant discovery from whole exome data. BMC Bioinformatics, 2016, 17, 403.	1.2	28
32	ChIP-seq in studying epigenetic mechanisms of disease and promoting precision medicine: progresses and future directions. Epigenomics, 2016, 8, 1239-1258.	1.0	22
33	EBSeq-HMM: a Bayesian approach for identifying gene-expression changes in ordered RNA-seq experiments. Bioinformatics, 2015, 31, 2614-2622.	1.8	93
34	Conserved Transcriptional Regulatory Programs Underlying Rice and Barley Germination. PLoS ONE, 2014, 9, e87261.	1.1	6
35	Epigenomic Analysis of Multilineage Differentiation of Human Embryonic Stem Cells. Cell, 2013, 153, 1134-1148.	13.5	689
36	Comparative RNA-seq Analysis in the Unsequenced Axolotl: The Oncogene Burst Highlights Early Gene Expression in the Blastema. PLoS Computational Biology, 2013, 9, e1002936.	1.5	125

SHULAN TIAN

#	Article	IF	CITATIONS
37	Identification of the Hemogenic Endothelial Progenitor and Its Direct Precursor in Human Pluripotent Stem Cell Differentiation Cultures. Cell Reports, 2012, 2, 553-567.	2.9	174
38	Proteomic and phosphoproteomic comparison of human ES and iPS cells. Nature Methods, 2011, 8, 821-827.	9.0	254
39	Optic Vesicle-like Structures Derived from Human Pluripotent Stem Cells Facilitate a Customized Approach to Retinal Disease Treatment. Stem Cells, 2011, 29, 1206-1218.	1.4	413
40	Efficient generation of transgene-free induced pluripotent stem cells from normal and neoplastic bone marrow and cord blood mononuclear cells. Blood, 2011, 117, e109-e119.	0.6	231
41	Identification of Hemogenic Endothelium and Its Direct Precursor in Human Embryonic Stem Cell Differentiation Cultures. Blood, 2011, 118, 1277-1277.	0.6	0
42	Loss-of-function of DELLA protein SLN1 activates GA signaling in barley aleurone. Acta Physiologiae Plantarum, 2010, 32, 789-800.	1.0	7
43	A Mesoderm-Derived Precursor for Mesenchymal Stem and Endothelial Cells. Cell Stem Cell, 2010, 7, 718-729.	5.2	269
44	Human Induced Pluripotent Stem Cells Free of Vector and Transgene Sequences. Science, 2009, 324, 797-801.	6.0	2,167
45	A study of the relationships between oligonucleotide properties and hybridization signal intensities from NimbleGen microarray datasets. Nucleic Acids Research, 2008, 36, 2926-2938.	6.5	38
46	Whole-Genome Analysis of Histone H3 Lysine 4 and Lysine 27 Methylation in Human Embryonic Stem Cells. Cell Stem Cell, 2007, 1, 299-312.	5.2	637
47	Induced Pluripotent Stem Cell Lines Derived from Human Somatic Cells. Science, 2007, 318, 1917-1920.	6.0	9,459
48	Genomic and Genetic Characterization of Rice Cen3 Reveals Extensive Transcription and Evolutionary Implications of a Complex Centromere. Plant Cell, 2006, 18, 2123-2133.	3.1	95
49	Transcription and Histone Modifications in the Recombination-Free Region Spanning a Rice Centromere[W]. Plant Cell, 2005, 17, 3227-3238.	3.1	107